Klinisk Biokemi i Norden Nr 3, vol. 18, 2006 - page 6-7

| 3 | 2006
| 3 | 2006
Klinisk Biokemi i Norden
Klinisk Biokemi i Norden
Nytt från NFKK
Jarkko Ihalainen
NFKK and the Nordic clinical chemistry
The 2005 NFKK sailing course of clinical communi-
cation was one of the good ideas of Per Simonsson.
Per has given a very big and valuable input to the
Nordic collaboration during his chairmanship. Tack
till Dig, Per. Väl gjort!
I have spent some of the hot summer of 2006
sitting in a cayak and thinking about the past and
future of the Association. My term began at the clo-
sure of the excellent Nordic congress in Copenhagen
in June. Almost simultaneously, Finland began it´s
period as a Presidency for the EU. The Nordic model
of welfare society was being discussed by our fel-
low Europeans as an example to follow. We do not
share a common organisation for social and health
services but most of our key values as professionals
are identical.
The NFKK celebrates it´s 60 years this year. The
history has been documented in SJCLI Suppl 1,
1997 and it can be accessed via the website of
NFKK. It is interesting to learn about the happy
skiing laboratorians in the middle of snow who
were the founders of the Nordic organisation – well
ahead of most of our national associations.
Thus, NFKK is not only result but more the reason
for the common nordic ideas in laboratory medi-
cine. These ideas have given the Nordic countries a
visible place in the world history of clinical labora-
tory science. I feel very humble when I look at the
list of previous chairpersons to NFKK.
NFKK stands in front of new challenges. The
clinical laboratory professionals all over the world
are discussing their future position in health-
care. The European Union has given birth to new
European co-operation and we need to balance the
international activities.
In order to understand and change our trajectory
in space-time it is not enough to know where we
are. We also need to look back and see where we
are coming from. Where we will be in the future is
the dependend variable.
As stressed by Per Simonsson in his last ”Nytt
från NFKK”, personal relationships between labo-
ratory professionals are the glue which keeps the
NFKK growing together.
Aktuellt från projektena av NFKK
1. Meeting about prenatal screening was held in
Copenhagen.
2. Pediatriska referensintervall: ett symposium tog
plats i NFKK kongress i Köpenhamn. Vi lärde
mycket om internationella projekt på samma
område. Arbetsgruppen fortsätter sin aktivitet.
3. Kritiska värden: jag förebereder ett enkäte till
nationella föreningar. Vi hade en bra, delvis
kritisk diskussion i symposiet i Köpenhamn.
Behöver vi telefon när vi har EDI?
4. GFR diskuterades också i Köpenhamn och arbets-
gruppen fortsätter.
Vi har också andra projekt på gång och föreningens
nya registrerade status i Danmark är också en spän-
nande nyhet till ledarskapen. Jag återkommer till de
här temor i fortsättiningen.
There is nothing positive about false positives-
just more testing, more time, more worry.
Fortunately, BNP testing can assist in ruling out heart failure in symptomatic patients, with
fewer false positives than NT-proBNP.
1-2
Bayer’s BNP assay uses widely accepted, very
specific antibodies for a high clinical specificity that correctly excludes CHF >97% of the
time.
1
This means getting the patient out of the line and onto the correct treatment pathway
faster, with less additional diagnostic testing. Backed by Bayer’s family of Immunoassay
analyzers, you get fast turnaround time delivering hundreds of tests per hour to rule out
more patients-positively.
Fewer false positives. More confidence. That’s innovation in the real world,
only from Bayer HealthCare.
1. ADVIA Centaur Assay Manual BNP - part # 06300497 Rev C June 2003, Bayer HealthCare LLC, Diagnostics
Division, Tarrytown, NY.
2. Based on a comparison of the data presented for the reference populations, as stated in the manufacturers’
instructions for use. Clinical specificity is calculated from the percentage of patients below the diagnostic cutpoints
presented for each assay.
www.labnews.com
©2005 Bayer HealthCare LLC. All rights reserved. Bayer and the Bayer Cross are trademarks of Bayer.
Cardiovascular Menu
BNP
CK-MB
Homocysteine
Myoglobin
Troponin I
What Are Your Heart Failure Tests
Resulting In?
On average, assays measuring NT-proB-
NP result in 9.3% more false positives
than Bayer’s BNP assays.
2
Bayer BNP
% FALSE POSITIVES
12
11
10
9
8
7
6
5
4
3
2
1
0
NT-proBNP
Percent (%)
11.97%
2.67%
1,2-3,4-5 8-9,10-11,12-13,14-15,16-17,18-19,20-21,22-23,24-25,26-27,...48
Powered by FlippingBook